G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference
G1 Therapeutics (Nasdaq: GTHX) announced that CEO Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference on February 11, 2021, at 2:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics (Nasdaq: GTHX) announced that CEO Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference on February 11, 2021, at 2:00 PM ET. This virtual event will feature a fireside chat, accessible via a live webcast. G1 Therapeutics is focused on developing innovative cancer therapies, including Trilaciclib, which has received Breakthrough Therapy Designation and is under FDA review with a PDUFA date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was +0.58%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take place on February 11, 2021 at 2:00 PM ET. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib received Breakthrough Therapy Designation and is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of February 15, 2021. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
Christine Rogers
Associate Director, Corporate Communications
984-365-2819
crogers@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.